<p>Cytek Biosciences（納斯達克代碼：CTKB - 獲取免費報告）於週三發佈了其財報。該公司報告本季度每股收益為（$0.04），低於市場共識預期的$0.01，差距為（$0.05），FiscalAI 報道。該公司本季度的收入為 5229 萬美元，而分析師預期為 5149 萬美元。Cytek Biosciences 的淨利潤率為負 3.27%，股本回報率為負 1.66%。Cytek Biosciences 更新了其 2025 財年的每股收益指引。</p>
<p>獲取 <strong>Cytek Biosciences</strong> 的提醒：</p>
<h2>Cytek Biosciences 股票表現</h2>
<p>週三午盤交易中，納斯達克代碼：CTKB 的股票上漲了$0.10，達到了$4.01。該公司的交易量為 956,227 股，而其平均交易量為 970,038 股。Cytek Biosciences 的 1 年最低價為$2.37，1 年最高價為$7.63。該公司的 50 日簡單移動平均為$3.92，200 日簡單移動平均為$3.60。該公司的市值為 5.1017 億美元，市盈率為-80.20，貝塔值為 1.33。</p>
<h2>對 Cytek Biosciences 的對沖基金看法</h2>
<p>對沖基金和其他機構投資者最近增加或減少了對該公司的持股。Federated Hermes Inc.在第二季度將其在 Cytek Biosciences 的持股增加了 150.9%。Federated Hermes Inc.現在擁有 7221 股該公司的股票，價值$25,000，此前在此期間購買了額外的 4343 股。Captrust Financial Advisors 在第二季度獲得了 Cytek Biosciences 的新股份，價值約$43,000。Tower Research Capital LLC TRC 在第二季度將其在 Cytek Biosciences 的持股增加了 338.1%。Tower Research Capital LLC TRC 現在擁有 19760 股該公司的股票，價值$67,000，此前在此期間獲得了額外的 15250 股。Quantbot Technologies LP 在第二季度獲得了 Cytek Biosciences 的新股份，價值約$84,000。最後，Strs Ohio 在第一季度獲得了 Cytek Biosciences 的新股份，價值約$105,000。機構投資者和對沖基金持有該公司 69.46% 的股票。</p>
<h2>分析師設定新目標價</h2>
<p>一些研究分析師最近對該股票進行了評論。Weiss Ratings 在 10 月 8 日的研究報告中重申了對 Cytek Biosciences 股票的 “賣出（e+）” 評級。Zacks Research 在 10 月 6 日的研究報告中將 Cytek Biosciences 的股票評級從 “持有” 上調至 “強力買入”。一位股票研究分析師給予該股票 “強力買入” 評級，兩位給予 “買入” 評級，兩位給予 “持有” 評級，兩位給予 “賣出” 評級。根據 MarketBeat.com 的數據，該公司目前的共識評級為 “持有”，共識目標價為$5.60。</p>
<p><strong>查看我們關於 CTKB 的最新研究報告</strong></p>
<h2>關於 Cytek Biosciences</h2>
<p>（獲取免費報告）</p>
<p>Cytek Biosciences, Inc 是一家細胞分析解決方案公司，提供細胞分析工具，以促進生物醫學研究和臨牀應用的科學進步。它提供 aurora 和 northern lights 系統，這些是光譜流式細胞儀，通過利用多個激光的熒光特徵來區分單個細胞上的熒光標籤，從而提供細胞分析；以及 aurora 細胞分選系統，利用全光譜分析技術進一步拓寬細胞分析的潛在應用；aurora CS 系統；amnis imagestream 成像流式細胞儀；guava muse 細胞分析儀；guava easycyte 流式細胞儀；以及 orion 試劑雞尾酒製備系統。</p>
<h2>另見</h2>
<ul>
<li>五隻我們更看好的股票，勝過 Cytek Biosciences</li>
<li>標普 500 股票向投資者傳達了什麼市場信息？</li>
<li>目前現金充裕的三隻高增長潛力股票</li>
<li>股票評級和推薦：理解分析師評級</li>
<li>為什麼 Vertical Aerospace 股票在這次飛行測試後可能會翻倍</li>
<li>如何使用股票篩選器尋找股票</li>
<li>亞馬遜：突破確認——接下來可能會去哪裏</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q1RLQg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q1RLQg"/></p>
<p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或評論發送至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資$1,000 在 Cytek Biosciences 嗎？</h2>
<p>在你考慮 Cytek Biosciences 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，建議現在購買，以便在更廣泛的市場注意到之前……而 Cytek Biosciences 並不在名單上。</p>
<p>雖然 Cytek Biosciences 目前在分析師中獲得了 “持有” 評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

CTKB

<p>Cytek Biosciences（納斯達克代碼：CTKB）公佈了季度財報，每股收益（EPS）為（$0.04），低於市場共識預期的$0.01。收入為$52.29 百萬，超過預期的$51.49 百萬。該公司的股本回報率為負 1.66%，淨利潤率為 3.27%。分析師對該股票的評級不一，市場共識評級為 “持有”，目標價為$5.60。機構投資者持有該公司 69.46% 的股份，近期交易中股價上漲至$4.01</p>

<p>Cytek Biosciences (NASDAQ:CTKB - Get Free Report) released its earnings results on Wednesday. The company reported ($0.04) EPS for the quarter, missing the consensus estimate of $0.01 by ($0.05), FiscalAI reports. The company had revenue of $52.29 million for the quarter, compared to analyst estimates of $51.49 million. Cytek Biosciences had a negative net margin of 3.27% and a negative return on equity of 1.66%. Cytek Biosciences updated its FY 2025 guidance to EPS.</p>
<div class="lb-trans"><p>Cytek Biosciences（納斯達克代碼：CTKB - 獲取免費報告）於週三發佈了其財報。該公司報告本季度每股收益為（$0.04），低於市場共識預期的$0.01，差距為（$0.05），FiscalAI 報道。該公司本季度的收入為 5229 萬美元，而分析師預期為 5149 萬美元。Cytek Biosciences 的淨利潤率為負 3.27%，股本回報率為負 1.66%。Cytek Biosciences 更新了其 2025 財年的每股收益指引。</p>
</div><p>Get <strong>Cytek Biosciences</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>Cytek Biosciences</strong> 的提醒：</p>
</div><h2>Cytek Biosciences Stock Performance</h2>
<div class="lb-trans"><h2>Cytek Biosciences 股票表現</h2>
</div><p>Shares of NASDAQ:CTKB traded up $0.10 during midday trading on Wednesday, reaching $4.01. The company had a trading volume of 956,227 shares, compared to its average volume of 970,038. Cytek Biosciences has a 1-year low of $2.37 and a 1-year high of $7.63. The company has a fifty day simple moving average of $3.92 and a two-hundred day simple moving average of $3.60. The firm has a market cap of $510.17 million, a price-to-earnings ratio of -80.20 and a beta of 1.33.</p>
<div class="lb-trans"><p>週三午盤交易中，納斯達克代碼：CTKB 的股票上漲了$0.10，達到了$4.01。該公司的交易量為 956,227 股，而其平均交易量為 970,038 股。Cytek Biosciences 的 1 年最低價為$2.37，1 年最高價為$7.63。該公司的 50 日簡單移動平均為$3.92，200 日簡單移動平均為$3.60。該公司的市值為 5.1017 億美元，市盈率為-80.20，貝塔值為 1.33。</p>
</div><h2>Hedge Funds Weigh In On Cytek Biosciences</h2>
<div class="lb-trans"><h2>對 Cytek Biosciences 的對沖基金看法</h2>
</div><p>Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Federated Hermes Inc. boosted its stake in Cytek Biosciences by 150.9% in the 2nd quarter. Federated Hermes Inc. now owns 7,221 shares of the company's stock worth $25,000 after purchasing an additional 4,343 shares during the period. Captrust Financial Advisors acquired a new stake in Cytek Biosciences during the 2nd quarter worth about $43,000. Tower Research Capital LLC TRC boosted its position in Cytek Biosciences by 338.1% during the 2nd quarter. Tower Research Capital LLC TRC now owns 19,760 shares of the company's stock worth $67,000 after acquiring an additional 15,250 shares during the period. Quantbot Technologies LP acquired a new stake in Cytek Biosciences during the 2nd quarter worth about $84,000. Finally, Strs Ohio acquired a new stake in shares of Cytek Biosciences during the first quarter worth approximately $105,000. Institutional investors and hedge funds own 69.46% of the company's stock.</p>
<div class="lb-trans"><p>對沖基金和其他機構投資者最近增加或減少了對該公司的持股。Federated Hermes Inc.在第二季度將其在 Cytek Biosciences 的持股增加了 150.9%。Federated Hermes Inc.現在擁有 7221 股該公司的股票，價值$25,000，此前在此期間購買了額外的 4343 股。Captrust Financial Advisors 在第二季度獲得了 Cytek Biosciences 的新股份，價值約$43,000。Tower Research Capital LLC TRC 在第二季度將其在 Cytek Biosciences 的持股增加了 338.1%。Tower Research Capital LLC TRC 現在擁有 19760 股該公司的股票，價值$67,000，此前在此期間獲得了額外的 15250 股。Quantbot Technologies LP 在第二季度獲得了 Cytek Biosciences 的新股份，價值約$84,000。最後，Strs Ohio 在第一季度獲得了 Cytek Biosciences 的新股份，價值約$105,000。機構投資者和對沖基金持有該公司 69.46% 的股票。</p>
</div><h2>Analysts Set New Price Targets</h2>
<div class="lb-trans"><h2>分析師設定新目標價</h2>
</div><p>A number of research analysts recently commented on the stock. Weiss Ratings reiterated a &#34;sell (e+)&#34; rating on shares of Cytek Biosciences in a research note on Wednesday, October 8th. Zacks Research upgraded shares of Cytek Biosciences from a &#34;hold&#34; rating to a &#34;strong-buy&#34; rating in a research note on Monday, October 6th. One equities research analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating, two have given a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of &#34;Hold&#34; and a consensus price target of $5.60.</p>
<div class="lb-trans"><p>一些研究分析師最近對該股票進行了評論。Weiss Ratings 在 10 月 8 日的研究報告中重申了對 Cytek Biosciences 股票的 “賣出（e+）” 評級。Zacks Research 在 10 月 6 日的研究報告中將 Cytek Biosciences 的股票評級從 “持有” 上調至 “強力買入”。一位股票研究分析師給予該股票 “強力買入” 評級，兩位給予 “買入” 評級，兩位給予 “持有” 評級，兩位給予 “賣出” 評級。根據 MarketBeat.com 的數據，該公司目前的共識評級為 “持有”，共識目標價為$5.60。</p>
</div><p><strong>Check Out Our Latest Research Report on CTKB</strong></p>
<div class="lb-trans"><p><strong>查看我們關於 CTKB 的最新研究報告</strong></p>
</div><h2>About Cytek Biosciences</h2>
<div class="lb-trans"><h2>關於 Cytek Biosciences</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（獲取免費報告）</p>
</div><p>Cytek Biosciences, Inc, a cell analysis solutions company, provides cell analysis tools that facilitates scientific advances in biomedical research and clinical applications. It offers aurora and northern lights systems, which are spectrum flow cytometers that delivers cell analysis by utilizing the fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells; and aurora cell sorter system that leverages full spectrum profiling technology to further broaden potential applications across cell analysis; aurora CS systems; amnis imagestream imaging flow cytometers; guava muse cell analyzers; guava easycyte flow cytometers; and orion reagent cocktail preparation systems.</p>
<div class="lb-trans"><p>Cytek Biosciences, Inc 是一家細胞分析解決方案公司，提供細胞分析工具，以促進生物醫學研究和臨牀應用的科學進步。它提供 aurora 和 northern lights 系統，這些是光譜流式細胞儀，通過利用多個激光的熒光特徵來區分單個細胞上的熒光標籤，從而提供細胞分析；以及 aurora 細胞分選系統，利用全光譜分析技術進一步拓寬細胞分析的潛在應用；aurora CS 系統；amnis imagestream 成像流式細胞儀；guava muse 細胞分析儀；guava easycyte 流式細胞儀；以及 orion 試劑雞尾酒製備系統。</p>
</div><h2>See Also</h2>
<div class="lb-trans"><h2>另見</h2>
</div><ul>
<li>Five stocks we like better than Cytek Biosciences</li>
<li>What Do S&amp;P 500 Stocks Tell Investors About the Market?</li>
<li>3 Cash-Rich Stocks With High Growth Potential Right Now</li>
<li>Stock Ratings and Recommendations: Understanding Analyst Ratings</li>
<li>Why Vertical Aerospace Stock Could Double After This Flight Test</li>
<li>How to Use Stock Screeners to Find Stocks</li>
<li>Amazon: Breakout Confirmed—Here’s Where It Could Go Next</li>
</ul>
<div class="lb-trans"><ul>
<li>五隻我們更看好的股票，勝過 Cytek Biosciences</li>
<li>標普 500 股票向投資者傳達了什麼市場信息？</li>
<li>目前現金充裕的三隻高增長潛力股票</li>
<li>股票評級和推薦：理解分析師評級</li>
<li>為什麼 Vertical Aerospace 股票在這次飛行測試後可能會翻倍</li>
<li>如何使用股票篩選器尋找股票</li>
<li>亞馬遜：突破確認——接下來可能會去哪裏</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q1RLQg" alt="" original-src="https://www.marketbeat.com/scripts/EarningsChart.ashx?Prefix=NASDAQ&amp;Symbol=CTKB"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或評論發送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Cytek Biosciences Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資$1,000 在 Cytek Biosciences 嗎？</h2>
</div><p>Before you consider Cytek Biosciences, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考慮 Cytek Biosciences 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cytek Biosciences wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，建議現在購買，以便在更廣泛的市場注意到之前……而 Cytek Biosciences 並不在名單上。</p>
</div><p>While Cytek Biosciences currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Cytek Biosciences 目前在分析師中獲得了 “持有” 評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

Cytek Biosciences（納斯達克股票代碼：CTKB）公佈季度收益結果